#6 - Catalyst Pharmaceuticals (NASDAQ:CPRX)
Biopharmaceutical companies frequently make enticing takeover targets. That’s usually because of the company’s pipeline. However, Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) offers investors a different proposition.
Catalyst is focused on developing and commercializing therapies for rare debilitating, chronic neuromuscular and neurological diseases in the United States. The company has three drugs in market. FIRDAPSE for rare neuromuscular diseases, AGAMREE for rare muscular dystrophy disease, and FYCOMPA for treating epileptic seizures. In the company’s third quarter earnings report, the company showed quarterly revenue that was up 25.3% YOY.
As of November 2024, the company has no drugs in its pipeline. But outside of its current collaborations, the company is actively looking for new partnerships that may allow it to expand its footprint outside the United States and to accelerate its growth into new therapeutic areas and larger markets.
Analysts have a consensus Buy rating on CPRX stock. The $31.14 price target would give investors 46% upside.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Read More - Current Price
- $21.74
- Consensus Rating
- Buy
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $31.14 (43.3% Upside)
